NASDAQ
114.49USD
-3.83 (-3.24%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
12.3B
P/E
—
EPS
—
Beta
0.46
52W range
28.66-122.21
Day range
111.79–118.53
Open
117.93
Prev close
118.32
Volume
1.8M
Avg volume
1.2M
Dividend
0.00
IPO
2004-04-14
https://seekingalpha.com/article/4927292-corcept-therapeutics-incorporated-cort-q2-2026-earnings-call-transcript · 7/29/2026+0.00
https://www.fool.com/coverage/filings/2026/07/20/a-corcept-cfo-set-his-selling-plan-the-month-the-stock-fell-50-here-s-what-investors-should-know/ · 7/21/2026+0.60
https://www.fool.com/coverage/filings/2026/07/20/a-corcept-director-holds-1-5-million-shares-through-a-50-crash-and-rebound/ · 7/21/2026+0.60
https://www.fool.com/coverage/etfs/2026/07/12/biotech-etfs-how-do-fbt-and-ibb-match-up-on-cost-structure-and-performance/ · 7/12/2026+0.00
https://www.fool.com/coverage/filings/2026/07/12/corcept-insider-sells-shares-after-an-fda-approval-and-a-usd1-05-billion-outlook/ · 7/12/2026+0.60
https://www.newsfilecorp.com/release/303973/Corton-Capital-Inc.-Announces-Filing-of-Preliminary-Prospectus-for-the-Corton-Rosenberg-Global-Macro-Fund · 7/3/2026+0.30
https://www.globenewswire.com/news-release/2026/06/18/3313896/0/en/Kuehn-Law-Encourages-Investors-of-Corcept-Therapeutics-Incorporated-to-Contact-Law-Firm.html · 6/18/2026-1.00
https://www.newsfilecorp.com/release/301825/Kuehn-Law-Encourages-Investors-of-Corcept-Therapeutics-Incorporated-to-Contact-Law-Firm · 6/17/2026-0.80
https://www.gurufocus.com/news/8904541/corcept-presents-new-data-at-ada-improved-outcomes-in-patients-receiving-a-glp1-with-difficulttocontrol-type-2-diabetes-and-hypercortisolism-treated-with-korlym · 6/6/2026+0.60
https://www.businesswire.com/news/home/20260606758364/en/Corcept-Presents-New-Data-at-ADA-Improved-Outcomes-in-Patients-Receiving-a-GLP-1-with-Difficult-to-Control-Type-2-Diabetes-and-Hypercortisolism-Treated-with-Korlym%C2%AE/ · 6/6/2026+0.60
https://www.businesswire.com/news/home/20260529589368/en/Corcept-Presents-New-Data-at-ASCO-2026-Lifyorli%E2%84%A2-Overall-Survival-Across-All-Subgroups-of-Patients-with-Platinum-Resistant-Ovarian-Cancer-Including-Those-with-Recent-Taxane-Exposure/ · 5/29/2026+0.60
https://www.zacks.com/stock/news/2923360/wall-street-analysts-believe-corcept-cort-could-rally-43-32-here-s-is-how-to-trade?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|consensus_price_target-2923360 · 5/19/2026+0.60
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
